Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer

Sunwoo Lee, Taejeong Oh, Hyuncheol Chung, SunYoung Rha, Changjin Kim, Youngho Moon, Benjamin D. Hoehn, Dongjun Jeong, Seunghoon Lee, Namkyu Kim, Chanhee Park, Miae Yoo, Sungwhan An

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Aberrant methylation of CpG islands in the promoter region of genes is a common epigenetic phenomenon found in early cancers. Therefore conducting genome-scale methylation studies will enhance our understanding of the epigenetic etiology behind carcinogenesis by providing reliable biomarkers for early detection of cancer. To discover novel hypermethylated genes in colorectal cancer by genome-wide search, we first defined a subset of genes epigenetically reactivated in colon cancer cells after treatment with a demethylating agent. Next, we identified another subset of genes with relatively down-regulated expression patterns in colorectal primary tumors when compared with normal appearing-adjacent regions. Among 29 genes obtained by cross-comparison of the two gene-sets, we subsequently selected, through stepwise subtraction processes, two novel genes, GABRA1 and LAMA2, as methylation targets in colorectal cancer. For clinical validation pyrosequencing was used to assess methylation in 134 matched tissue samples from CRC patients. Aberrant methylation at target CpG sites in GABRA1 and LAMA2 was observed with high frequency in tumor tissues (92.5% and 80.6%, respectively), while less frequently in matched tumor-adjacent normal tissues (33.6% for GABRA1 and 13.4% for LAMA2). Methylation levels in primary tumors were not significantly correlated with clinico- pathological features including age, sex, survival and TNM stage. Additionally, we found that ectopic overexpression of GABRA1 in colon cancer cell lines resulted in strong inhibition of cell growth. These results suggest that two novel hypermethylated genes in colorectal cancer, GABRA1 and LAMA2, may have roles in colorectal tumorigenesis and could be potential biomarkers for the screening and the detection of colorectal cancer in clinical practice.

Original languageEnglish
Pages (from-to)889-898
Number of pages10
JournalInternational Journal of Oncology
Volume40
Issue number3
DOIs
Publication statusPublished - 2012 Mar 1

Fingerprint

DNA Methylation
Genetic Markers
Colorectal Neoplasms
Methylation
Genes
Epigenomics
Colonic Neoplasms
Neoplasms
Carcinogenesis
Biomarkers
Genome
CpG Islands
Early Detection of Cancer
Genetic Promoter Regions
Cell Line
Survival
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lee, Sunwoo ; Oh, Taejeong ; Chung, Hyuncheol ; Rha, SunYoung ; Kim, Changjin ; Moon, Youngho ; Hoehn, Benjamin D. ; Jeong, Dongjun ; Lee, Seunghoon ; Kim, Namkyu ; Park, Chanhee ; Yoo, Miae ; An, Sungwhan. / Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer. In: International Journal of Oncology. 2012 ; Vol. 40, No. 3. pp. 889-898.
@article{2ab9d243557f4a94a33994a385711e58,
title = "Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer",
abstract = "Aberrant methylation of CpG islands in the promoter region of genes is a common epigenetic phenomenon found in early cancers. Therefore conducting genome-scale methylation studies will enhance our understanding of the epigenetic etiology behind carcinogenesis by providing reliable biomarkers for early detection of cancer. To discover novel hypermethylated genes in colorectal cancer by genome-wide search, we first defined a subset of genes epigenetically reactivated in colon cancer cells after treatment with a demethylating agent. Next, we identified another subset of genes with relatively down-regulated expression patterns in colorectal primary tumors when compared with normal appearing-adjacent regions. Among 29 genes obtained by cross-comparison of the two gene-sets, we subsequently selected, through stepwise subtraction processes, two novel genes, GABRA1 and LAMA2, as methylation targets in colorectal cancer. For clinical validation pyrosequencing was used to assess methylation in 134 matched tissue samples from CRC patients. Aberrant methylation at target CpG sites in GABRA1 and LAMA2 was observed with high frequency in tumor tissues (92.5{\%} and 80.6{\%}, respectively), while less frequently in matched tumor-adjacent normal tissues (33.6{\%} for GABRA1 and 13.4{\%} for LAMA2). Methylation levels in primary tumors were not significantly correlated with clinico- pathological features including age, sex, survival and TNM stage. Additionally, we found that ectopic overexpression of GABRA1 in colon cancer cell lines resulted in strong inhibition of cell growth. These results suggest that two novel hypermethylated genes in colorectal cancer, GABRA1 and LAMA2, may have roles in colorectal tumorigenesis and could be potential biomarkers for the screening and the detection of colorectal cancer in clinical practice.",
author = "Sunwoo Lee and Taejeong Oh and Hyuncheol Chung and SunYoung Rha and Changjin Kim and Youngho Moon and Hoehn, {Benjamin D.} and Dongjun Jeong and Seunghoon Lee and Namkyu Kim and Chanhee Park and Miae Yoo and Sungwhan An",
year = "2012",
month = "3",
day = "1",
doi = "10.3892/ijo.2011.1245",
language = "English",
volume = "40",
pages = "889--898",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

Lee, S, Oh, T, Chung, H, Rha, S, Kim, C, Moon, Y, Hoehn, BD, Jeong, D, Lee, S, Kim, N, Park, C, Yoo, M & An, S 2012, 'Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer', International Journal of Oncology, vol. 40, no. 3, pp. 889-898. https://doi.org/10.3892/ijo.2011.1245

Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer. / Lee, Sunwoo; Oh, Taejeong; Chung, Hyuncheol; Rha, SunYoung; Kim, Changjin; Moon, Youngho; Hoehn, Benjamin D.; Jeong, Dongjun; Lee, Seunghoon; Kim, Namkyu; Park, Chanhee; Yoo, Miae; An, Sungwhan.

In: International Journal of Oncology, Vol. 40, No. 3, 01.03.2012, p. 889-898.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer

AU - Lee, Sunwoo

AU - Oh, Taejeong

AU - Chung, Hyuncheol

AU - Rha, SunYoung

AU - Kim, Changjin

AU - Moon, Youngho

AU - Hoehn, Benjamin D.

AU - Jeong, Dongjun

AU - Lee, Seunghoon

AU - Kim, Namkyu

AU - Park, Chanhee

AU - Yoo, Miae

AU - An, Sungwhan

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Aberrant methylation of CpG islands in the promoter region of genes is a common epigenetic phenomenon found in early cancers. Therefore conducting genome-scale methylation studies will enhance our understanding of the epigenetic etiology behind carcinogenesis by providing reliable biomarkers for early detection of cancer. To discover novel hypermethylated genes in colorectal cancer by genome-wide search, we first defined a subset of genes epigenetically reactivated in colon cancer cells after treatment with a demethylating agent. Next, we identified another subset of genes with relatively down-regulated expression patterns in colorectal primary tumors when compared with normal appearing-adjacent regions. Among 29 genes obtained by cross-comparison of the two gene-sets, we subsequently selected, through stepwise subtraction processes, two novel genes, GABRA1 and LAMA2, as methylation targets in colorectal cancer. For clinical validation pyrosequencing was used to assess methylation in 134 matched tissue samples from CRC patients. Aberrant methylation at target CpG sites in GABRA1 and LAMA2 was observed with high frequency in tumor tissues (92.5% and 80.6%, respectively), while less frequently in matched tumor-adjacent normal tissues (33.6% for GABRA1 and 13.4% for LAMA2). Methylation levels in primary tumors were not significantly correlated with clinico- pathological features including age, sex, survival and TNM stage. Additionally, we found that ectopic overexpression of GABRA1 in colon cancer cell lines resulted in strong inhibition of cell growth. These results suggest that two novel hypermethylated genes in colorectal cancer, GABRA1 and LAMA2, may have roles in colorectal tumorigenesis and could be potential biomarkers for the screening and the detection of colorectal cancer in clinical practice.

AB - Aberrant methylation of CpG islands in the promoter region of genes is a common epigenetic phenomenon found in early cancers. Therefore conducting genome-scale methylation studies will enhance our understanding of the epigenetic etiology behind carcinogenesis by providing reliable biomarkers for early detection of cancer. To discover novel hypermethylated genes in colorectal cancer by genome-wide search, we first defined a subset of genes epigenetically reactivated in colon cancer cells after treatment with a demethylating agent. Next, we identified another subset of genes with relatively down-regulated expression patterns in colorectal primary tumors when compared with normal appearing-adjacent regions. Among 29 genes obtained by cross-comparison of the two gene-sets, we subsequently selected, through stepwise subtraction processes, two novel genes, GABRA1 and LAMA2, as methylation targets in colorectal cancer. For clinical validation pyrosequencing was used to assess methylation in 134 matched tissue samples from CRC patients. Aberrant methylation at target CpG sites in GABRA1 and LAMA2 was observed with high frequency in tumor tissues (92.5% and 80.6%, respectively), while less frequently in matched tumor-adjacent normal tissues (33.6% for GABRA1 and 13.4% for LAMA2). Methylation levels in primary tumors were not significantly correlated with clinico- pathological features including age, sex, survival and TNM stage. Additionally, we found that ectopic overexpression of GABRA1 in colon cancer cell lines resulted in strong inhibition of cell growth. These results suggest that two novel hypermethylated genes in colorectal cancer, GABRA1 and LAMA2, may have roles in colorectal tumorigenesis and could be potential biomarkers for the screening and the detection of colorectal cancer in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84863151977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863151977&partnerID=8YFLogxK

U2 - 10.3892/ijo.2011.1245

DO - 10.3892/ijo.2011.1245

M3 - Article

C2 - 22038115

AN - SCOPUS:84863151977

VL - 40

SP - 889

EP - 898

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -